<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087200</url>
  </required_header>
  <id_info>
    <org_study_id>OSS 15.161</org_study_id>
    <nct_id>NCT04087200</nct_id>
  </id_info>
  <brief_title>Protective Effect of Early High Dose stATins On Cardiovascular and Renal Events in Acute Coronary Syndrome</brief_title>
  <acronym>PRATO-ACS</acronym>
  <official_title>The Protective Effect of Early High Dose High-intensity Statins on Cardiovascular and Renal Events in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Cardiopatici Toscani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda USL 4 Prato</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Cardiopatici Toscani</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registration of all ACS patients (STEMI and NSTEMI) admitted to the cardiology ward and
      scheduled for early invasive strategy. The aim is to evaluate the protective effects of early
      (on admission) high-dose high-potency statin therapy on early and mid-term cardiac and renal
      events in this subset of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statin-naive patients and those on statin therapy with ACS who are admitted to the cardiology
      ward of our public (National Health Service) hospital and are scheduled for early invasive
      strategy receive immediately on admission, always before angiographic procedure, high-dose
      statin therapy. Either atorvastatin 80 mg or rosuvastatin 40 mg is administered at the
      discretion of the physician. During hospitalization various pertinent cardiac and renal
      parameters, including hematological, angiographic, clinical data are registered in a
      dedicated database. Clinical follow-up and hematological analysis are done 1 month after
      discharge. A second follow-up, either clinical or by telephone, is done 1 year after
      discharge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Acute renal function changes</measure>
    <time_frame>Within 72 hours after hospital admission</time_frame>
    <description>Changes in creatinine and/or cystatine values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory profile changes</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Changes from baseline in CRP values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid profile changes</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Changes from baseline in cholesterol values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet count</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Changes from baseline in platelet count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet volume</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Changes from baseline in platelet volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet aggregation profile</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Changes from baseline in platelet reactivity (Verify Now)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular adverse events</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Death, myocardial infarction, stroke or coronary revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function changes</measure>
    <time_frame>Changes from baseline at 1 month</time_frame>
    <description>glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular and renal adverse events</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Death, myocardial infarction, stroke, coronary revascularization or glomerular filtration rate reduction &gt; = 25% compared to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Impact of age and frailty profile on primary and secondary outcomes</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Frailty evaluation (combination of FRAIL scale questionnaire and hand-grip strength measurement)</description>
  </other_outcome>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Statin-naive patients and those on statin therapy with ACS (both STEMI and NSTEMI)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute coronary syndrome (ST elevation and non ST elevation)

          -  Early invasive strategy

        Exclusion Criteria:

          -  contraindication to statin therapy

          -  refusal of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Toso, MD</last_name>
    <phone>00393387982507</phone>
    <email>anna.toso@libero.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario Leoncini, MD</last_name>
    <phone>0039-0574803738</phone>
    <email>leoncini.mario@tiscali.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Division, Prato Hospital</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Toso, MD</last_name>
      <phone>+390574434396</phone>
      <email>anna.toso@libero.it</email>
    </contact>
    <contact_backup>
      <last_name>Mario Leoncini, MD</last_name>
      <phone>+390574434270</phone>
      <email>leoncini.mario@tiscali.it</email>
    </contact_backup>
    <investigator>
      <last_name>Francesco Bellandi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Tropeano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauro Maioli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Musilli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Cardiopatici Toscani</investigator_affiliation>
    <investigator_full_name>Anna Toso</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>Acute kidney injury</keyword>
  <keyword>Renal function</keyword>
  <keyword>Statin therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

